AnaCardio, a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure, has announced the completion of a USD 19 million (SEK 205 million) Series A extension financing round, co-led by new international investors Novo Holdings, Pureos Bioventures and Sound Bioventures. Current investors Flerie, Industrifonden, and Fredrik and Ann-Helene Ljungström, also participated to complete the round. The raised funds will be used to complete the phase 1b/2a GOAL-HF1 study, and to prepare and initiate start-up activities for the subsequent phase 2b study.
KANTER Advokatbyrå has acted as legal advisor to AnaCardio.